A panelist discusses how real-world data presented at the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) ...

Skin and subcutaneous diseases account for 44.84 million DALYs globally in 2021, ranking seventh in disability burden.

The FDA approved dupilumab (Dupixent) for chronic spontaneous urticaria (CSU) in patients 12 years and older, the first new ...

Chronic spontaneous urticaria is chronic inflammatory skin disease driven in part by type 2 inflammation, which causes sudden ...

Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to treat chronic spontaneous urticaria in patients 12 years and older whose hives ...

Many people experience an itchy scalp at some point. It’s usually not a sign of a serious medical condition and can, in most ...

Some topical cannabinoid therapies could be a safe and effective treatment for patients with atopic dermatitis (AD) says a ...

multi-target therapeutics for atopic dermatitis and other severe and common skin diseases (PRNewsfoto/Alphyn Biologics) Zabalafin Hydrogel offers the potential to be the first singular ...

multi-target therapeutics for atopic dermatitis and other severe and common skin diseases (PRNewsfoto/Alphyn Biologics) Zabalafin Hydrogel offers the potential to be the first singular comprehensive ...

Perioral dermatitis is a skin condition characterized by a rash around the mouth. It is one type of dermatitis, which is a general term for skin irritation. In the word “perioral,” “peri ...

In this video, Peter Lio, MD, discussed updates on topical agents, biologics and drugs in the pipeline in atopic dermatitis from presentations at the American Academy of Dermatology meeting.

highlighted research from the American Academy of Dermatology meeting and said his biggest takeaway from the meeting was that dermatologists are in “the decade of atopic dermatitis.” ...